MARKET WIRECNBC • 2h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why IMMX Stock slipped -1.78% Today — RQD Quant Desk Flash
$7.98 -1.78% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $7.94
Immix Biopharma Inc. (IMMX) carries a Roarable Rating of E (Strong Sell) with 33/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $661.6M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $7.94 (-0.51%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (33/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.9% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-11.3% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for IMMX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (33/100 Composite)
🔍 WHY IMMX SCORES 33/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (30% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (24% of score)
FRED Regime × Technicals: 42% of 52W Range • RSI-14 at 30.3 (OVERSOLD (<32))
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$9.46-15.6% Next Q
41
Q2 (-2Q)Grade E$7.98+2.1% Next Q
38
Q3 (-1Q)Grade E$8.15-2.1% Next Q
36
CurrentGrade E$7.98-8.9% Hist 90D α
33
Trajectory: D (41) → E (33)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a IMMX Turnaround Squeeze
While IMMX currently carries a cautious 33/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($11.02) and Max Pain ($8.38) forces dealer call-delta covering toward $15.86.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $IMMX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “IMMX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why IMMX Stock slipped -1.78% Today — RQD Quant Desk Flash
Immix Biopharma Inc. (IMMX) slipped -1.78% to $7.98, trading at 42% of its 52-week range ($2.85 – $15.1). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 42% of its 52-week range ($2.85 – $15.1) with RSI-14 at 30.3 (OVERSOLD (<32)).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $7.98 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live IMMX Headlines & Catalysts
MARKET WIRECNBC • 3h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 4h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 5h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 6h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 7h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 7h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 7h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring IMMX)
- ✓Walkthrough of IMMX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
IMMX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -10.64%🛡️ HOLDING TREND SUPPORT
2026-10-30O $7.86H $8.10L $7.56C $7.98VOL 1.38M
RES: $17.93SUP: $7.60SMA50: $11.02SMA200: $9.48
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
IMMX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on IMMX today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for IMMX. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for IMMX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IMMX)
Health Care Rank #864 of 1016
⚔️ ANL vs IMMX Full Matrix →
1. Head-to-Head Health Care Peer Comparison (IMMX vs. ANL, LXRX, ABUS, BCAX)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Immix Biopharma Inc. (IMMX) ranks #864 by composite RQD confidence (33/100, grade E) and #407 by equity capitalization ($661.6M). Within this direct 5-issuer industry benchmark cohort, IMMX leads on earnings valuation at N/A trailing P/E, while LXRX leads on capital efficiency and profitability with -31.5% ROIC and 96.0% gross margin. ANL currently holds the highest overall quantitative score in the immediate peer group at 52/100 (D+) compared with IMMX at 33/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| IMMX
ACTIVE
Immix Biopharma Inc. | E | 33/100 | — | — | -35.0% | -1.78% | $661.6M | Benchmark Subject |
| ANL Adlai Nortye Group Ltd. | D+ | 52/100 | — | — | — | +0.78% | $662.0M | /anl-vs-immx → |
| LXRX Lexicon Pharmaceuticals Inc. | D- | 39/100 | — | 96.0% | -31.5% | -0.34% | $658.5M | /lxrx-vs-immx → |
| ABUS Arbutus Biopharma Corporation | E | 22/100 | — | — | -35.0% | -0.93% | $656.0M | /abus-vs-immx → |
| BCAX Bicara Therapeutics Inc. | D | 45/100 | — | — | -35.0% | -0.31% | $643.9M | /bcax-vs-immx → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001873835In its most recent audited fiscal period (FY2025, filed 2025-12-31), Immix Biopharma Inc. (IMMX) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$29.4M, operating cash flow of -$23.9M, and free cash flow of -$24.7M (-56.4% YoY). On the balance sheet, IMMX closed FY2025 with $104.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$29.4M | -$23.9M | -$24.7M | $104.8M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$21.6M | -$14.6M | -$15.8M | $22.9M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$15.4M | -$11.4M | -$11.4M | — | — |
3. IMMX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs IMMX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Immix Biopharma Inc. (NASDAQ: IMMX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $7.98 (-1.78% 1D, market cap $661.6M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, IMMX ranks #864 in composite RQD confidence.
How does IMMX compare to ANL and LXRX in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), IMMX carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ANL (Adlai Nortye Group Ltd.) holds a D+ grade (52/100 RQD, P/E N/A, ROIC —, cap $662.0M) and LXRX (Lexicon Pharmaceuticals Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -31.5%, cap $658.5M). Among the 5-stock peer group, IMMX leads on earnings multiple (N/A) while LXRX leads on capital efficiency (-31.5% ROIC).
What are the biggest fundamental strengths and SEC risk factors for IMMX?
Per IMMX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001873835), Immix Biopharma Inc. generated $0 in revenue, -$29.4M in net income, and -$24.7M in free cash flow against $104.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is IMMX trading relative to its 50-day, 200-day, and 52-week technical levels?
IMMX last traded at $7.98 (-1.78% on volume of 1,073,810 shares), positioning the stock -27.59% below its 50-day simple moving average ($11.02) and -15.82% below its 200-day simple moving average ($9.48). Across its 52-week range of $2.85 to $15.10, IMMX sits at the 41.9% percentile with a 14-day RSI of 30.3 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($6.98 to $8.98).
IMMX Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is IMMX stock moving today?
Why IMMX Stock slipped -1.78% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.